DDIs between corticosteroids and cobicistat or ritonavir

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1766卷 / 1期
关键词：
D O I：
10.1007/s40278-019-66078-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [1] Pharmacokinetic Differences Between Cobicistat and Ritonavir on Warfarin
    Fulco, Patricia Pecora
    Bannister, Laura Hill
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (11) : 1165 - 1166
  • [2] Cushing's syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case-control study in the French Pharmacovigilance Database
    Peyro-Saint-Paul, Laure
    Besnier, Paul
    Demessine, Ludivine
    Biour, Michel
    Hillaire-Buys, Dominique
    de Canecaude, Claire
    Fedrizzi, Sophie
    Parienti, Jean-Jacques
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (11) : 3291 - 3294
  • [3] Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women
    Eke, Ahizechukwu C.
    Mirochnick, Mark
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (07) : 523 - 525
  • [4] Antiretroviral Boosting by Cobicistat, a Structural Analog of Ritonavir
    Greenblatt, David J.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (05): : 335 - 337
  • [5] Risk of adrenal suppression with cobicistat + corticosteroids
    Reactions Weekly, 2016, 1627 (1) : 4 - 4
  • [6] Ritonavir/Cobicistat-Induced Cushing Syndrome in HIV Patients Treated With Non-Oral Corticosteroids: A Call for Action?
    Cattaneo, Dario
    Giacomelli, Andrea
    Pagani, Gabriele
    Filice, Carlo
    Gervasoni, Cristina
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2021, 361 (01): : 137 - 139
  • [7] Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
    Dekkers, Bart G. J.
    Bierman, Wouter F. W.
    Touw, Daan J.
    Alffenaar, Jan-Willem C.
    AIDS, 2019, 33 (06) : 1100 - 1102
  • [8] In vitro inhibition of human UGT isoforms by ritonavir and cobicistat
    Algeelani, Sara
    Alam, Novera
    Hossain, Md Amin
    Mikus, Gerd
    Greenblatt, David J.
    XENOBIOTICA, 2018, 48 (08) : 764 - 769
  • [9] Tolerability, efficacy and cost savings associated with switching ritonavir to cobicistat
    Pires, S.
    Cavilla, S.
    Churchill, D.
    HIV MEDICINE, 2018, 19 : S30 - S31
  • [10] Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir
    Thai Nguyen
    McNicholl, Ian
    Custodio, Joseph M.
    Szwarcberg, Javier
    Piontkowsky, David
    AIDS REVIEWS, 2016, 18 (02) : 101 - 111
12345